Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia

British Journal of Haematology
Ofir WolachDaniel J DeAngelo

Abstract

Significant advances have been made in recent years in the field of Philadelphia-negative acute lymphoblastic leukaemia (ALL). New insights into the biology and genetics of ALL as well as novel clinical observations and new drugs are changing the way we diagnose, risk-stratify and treat adult patients with ALL. New genetic subtypes and alterations refine risk stratification and uncover new actionable therapeutic targets. The incorporation of more intensive, paediatric and paediatric-inspired approaches for young adults seem to have a positive impact on survival in this population. Minimal residual disease at different time points can assist in tailoring risk-adapted interventions for patients based on individual response. Finally, novel targeted approaches with monoclonal antibodies, immunotherapies and small molecules are moving through clinical development and entering the clinic. The aim of this review is to consolidate the abundance of emerging data and to review and revisit the concepts of risk-stratification, choice of induction and post-remission strategies as well as to discuss and update the approach to specific populations with ALL, such as young adult, elderly/unfit and relapsed/refractory patients with ALL.

References

Feb 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Forida Y MortuzaLetizia Foroni
Aug 15, 2003·The New England Journal of Medicine·Ching-Hon PuiMelissa M Hudson
Sep 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xavier ThomasDenis Fiere
Oct 22, 2004·Seminars in Oncology·Nadia N Laack, Paul D Brown
Oct 1, 2005·Blood·Monika BrüggemannUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Mar 25, 2006·Blood·Hillard M LazarusUNKNOWN Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom
May 16, 2006·Cancer·Juan-Manuel SanchoUNKNOWN Programa para el Estudio y Tratamiento de Hemopatias Malignas Group
Oct 13, 2006·Blood·Adele K FieldingUNKNOWN Eastern Cooperative Oncology Group
Jul 6, 2007·Leukemia·E TavernierUNKNOWN Australasian Leukaemia and Lymphoma Group
Jul 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claudia D BaldusWolf K Hofmann
Apr 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Josep-María RiberaJuan-José Ortega
Dec 23, 2008·Seminars in Hematology·Nicola Gökbuget, Dieter Hoelzer
Jan 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Françoise HuguetHervé Dombret
Jan 9, 2009·The New England Journal of Medicine·Charles G MullighanUNKNOWN Children's Oncology Group
Jan 17, 2009·The Lancet Oncology·Elaine Coustan-SmithDario Campana
Jun 26, 2009·The New England Journal of Medicine·Ching-Hon PuiMary V Relling
Sep 24, 2009·Haematologica·Sébastien MauryUNKNOWN Group for Research on Adult Acute Lymphoblastic Leukemia
Feb 11, 2010·Haematologica·Albert OriolUNKNOWN Programa Español de Tratamiento en Hematologia Group
Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Deborah A ThomasHagop M Kantarjian
Oct 16, 2010·The Lancet Oncology·Hiroto Inaba, Ching-Hon Pui
Oct 19, 2010·Haematologica·Nicola GökbugetUNKNOWN German Multicenter Study Group for Adult ALL and the European Working Group for Adult ALL
Oct 26, 2010·Haematologica·Mathilde Hunault-BergerUNKNOWN Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
Mar 11, 2011·Nature·Charles G MullighanJames R Downing

❮ Previous
Next ❯

Citations

Jan 9, 2020·Current Opinion in Hematology·Ofir Wolach, Richard M Stone
Sep 26, 2019·Bone Marrow Transplantation·Ana Lisa BasquieraUNKNOWN Grupo Argentino de Trasplante de Médula Ósea (GATMO)
Mar 28, 2019·Expert Opinion on Investigational Drugs·Marte Karen BrattåsØystein Bruserud
Dec 4, 2019·JCO Oncology Practice·Rebecca E MacDonell-YilmazJennifer Greene Welch
Feb 20, 2020·Therapeutic Advances in Hematology·Francesca CarobolanteRenato Bassan
Dec 10, 2020·Experimental Hematology & Oncology·Le Li, Ying Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2022 Meta ULC. All rights reserved